DOCSLIB.ORG

הקונגרס הבינ;Quot&ל השני לסוכרת ע;Quot&ש בילדריג'י, ביה;Quot&ח לניאדו

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Second International Congress of the Bildirici Diabetes Center, Laniado Hospital הקונגרס הבינ"ל השני לסוכרת ע"ש בילדריג'י, ביה"ח לניאדו 24-25.01.12 וואהל סנטר, אוניברסיטת בר אילן the Wohl Center, Bar Ilan University, Ramat Gan, Israel יו"ר הכנס פרופ' איתמר רז ד"ר מרק ניבן מנהל היחידה לסוכרת, המרכז הרפואי הדסה עין מנהל היחידה לאנדוקרינולוגיה וסוכרת, כרם, ירושלים, יו“ר המועצה הלאומית לסוכרת בי"ח לניאדו, נתניה Speakers from abroad: Prof. Jaakko Tuomilheto Dr. Peter Rossing Prof. Ralph De Fronzo Dr. Martin M. Grajower Prof. Jesse Roth, Prof. Roy E. Weiss Prof. Samuel C. Durso Prof. Michael A. Nauck Prof. Harold Lebovitz מזכירות הכנס Day 1 Tuesday 24 January 2012 9:00 Opening Ceremony 09:00-09:20 Greetings Dr. Mark J. Niven, Director of Endocrine and Diabetes Unit, Laniado Hospital, Netanya, Israel Prof. Itamar Raz, Chairman of the National Council of Diabetes Dr. Avinoam Shkolnik, Medical Director, Laniado Hospital, Netanya Plenary Session 1 09:20-09:40 What can we learn from outcome studies versus clinical experience in the treatment of Diabetes? Prof. Itamar Raz, Chairman of the National Council of Diabetes 09:40-10:05 Type 2 Diabetes – detection and prevention Prof. Jaakko Tuomilehto, Professor of Public Health, University of Helsinki, Helsinki, Finland and Professor of Vascular Prevention, Danube-University Krems, Krems, Austria 10:05-10:30 Insulin Resistance, T2DM, ASCVD: The Missing Links Prof. Ralph A. DeFronzo, MD, Professor of Medicine, Chief, Diabetes Division, UTHSCSA and Deputy Director Texas Diabetes Institute 10:30-10:50 Questions and panel discussion 10:50-11:10 Coffee Break Parallel Sessions 1 Diabetes and Cardiovascular disease Renal disease and Hypertension Chairmen: Dr. Ron Lior, Specialist in Cardiology and Internal Medicine, Chairmen: Prof. Yoram Yagil, Professor of Medicine, Head, Department of Laniado Hospital, Netanya Nephrology and Hypertension, Head, Laboratory for Molecular Medicine and Prof. Moti Ravid, Medical Director, Mayanei HaYeshua Medical Center, Bnei Israeli Rat Genome Center, Clara and Alejandro Stransky Chair in Nephrology, Brak Barzilai Medical Center Campus, Ashkelon Prof. Geoffrey Boner, Specialist Nephrologist,Director (retired) of Dept of Nephrology, Rabin Medical Center - Belinson Campus, Associate Professor (retired) Dept of Medicine, Sackler Medical Faculty, Tel Aviv University, Nephrology Consultant, Bildirici Diabetes Center, Laniado Hospital, Faculty of Health Sciences, Ben-Gurion University 11:10-11:30 Hypoglycemia and Cardiovascular risk The pathogenetic mechanisms of renal involvement in patients Prof. Harold Lebovitz, Professor of Medicine, Division of Endocrinology and with Diabetes Mellitus Metabolism/Diabetes at the State University of New York, Health Sciences Prof. Yoram Yagil, Professor of Medicine, Head, Department of Nephrology Center at Brooklyn, NY and Hypertension, Head, Laboratory for Molecular Medicine and Israeli Rat Genome Center, Clara and Alejandro Stransky Chair in Nephrology, Barzilai Medical Center Campus, Ashkelon 11:30-11:50 Is hyperglycemia a CV risk factor – recent trials of CVD prevention: Nephrological assessment and follow-up of the diabetic patient answers or just more questions? Prof. Geoffrey Boner, Specialist Nephrologist, Director (retired) of Dept of Prof. Michael A. Nauck, Head Physician at Diabeteszentrum Bad Lauterberg, Nephrology, Rabin Medical Center - Belinson Campus,Associate Professor Bad Lauterberg, Germany (retired) Dept of Medicine, Sackler Medical Faculty, Tel Aviv University, Nephrology Consultant, Bildirici Diabetes Center, Laniado Hospital, Faculty of Health Sciences, Ben-Gurion University 11:50-12:10 The heart in Diabetes – More than just macrovascular disease? The Diabetic patient with hypertension - What treatment and Prof. Morris Mosseri, Head of Cardiology Division, Meir Medical Center, Kfar what target for blood pressure reduction? Saba Prof. Ehud Grossman, Professor of Medicine, Sackler school of medicine, Tel Aviv University, Head of Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel Hashomer 12:10-12:30 Anti-Platelet therapy in Diabetes – More harm or good? RAS suppression in diabetic nephropathy: present day options Dr. Galia Spectre, Hematology departement and coagulation unit Hadassah, and what does the future hold? Jerusalem Dr. Peter Rossing, Head of Research, Chief physician, Steno Diabetes Center, Denmark 12:30-13:00 Questions/Panel discussion Questions/Panel discussion 13:00-14:00 Lunch Diabetes and stages of life Therapeutics Chairmen: Dr. Orna Dali-Gottfried, Director of the juvenile diabetes center Chairmen: Dr. Julio Wainstein, Head of Diabetes Unit, The E. Wolfson Medical Center and pediatrics endocrinology, Ziv Medical Center, Zefat Prof. Ardon Rubinstein, Director of the Metabolic Diseases and Lipids Unit at the Tel Aviv Medical Center 14:00-14:20 Diabetes and pregnancy – Before, during and after Incretin Therapy 2012 and beyond Prof. Moshe Hod, Director, Division of Maternal Fetal Medicine, Helen Prof. Michael A. Nauck, Head Physician at Diabeteszentrum Bad Lauterberg, Schneider Hospital for Women, Rabin Medical Center, Sackler Faculty of Bad Lauterberg, Germany Medicine, Tel-Aviv University 14:20-14:40 Diabetes in children and youth – The long term view New drugs on the horizon Dr. Ram Weiss, Department of Human Metabolism and Nutrition Section of Prof. Harold Lebovitz, Professor of Medicine, Division of Endocrinology and Pediatric Endocrinology Hadassah, Hebrew University, Jerusalem Metabolism/Diabetes at the State University of New York, Health Sciences Center at Brooklyn, NY 14:40-15:00 Religious and cultural factors and diabetes [dietary variation, Should A1C targets be individualized for all people with Diabetes? fasting, acceptability of treatment modalities eg. injection/pump/ Prof. Micha Rapoport, Director of Internal Medicine "C" & Diabetes Service, smbg on Shabbat, stigma] Chairman of the Internal Medicine Division, Assaf Harofeh Medical Center, Dr. Yosef Kleinman, Head of the Internal Medicine Department, Bikur Cholim Zerifin Hospital, Jerusalem Rabbi Dr. Elie Abadie, The Edmond J. Safra Synagogue, NY; Director, Jacob E. Safra Institute of Sephardic Studies, Yeshiva Universitry, NY; Gastroenterologist in Brooklyn, NY Dr. Martin M. Grajower, Assistant Clinical Professor of Medicine, Albert Einstein College of Medicine, Riverdale, NY 15:00-15:15 Questions/Discussion Questions/Discussion 15:15-15:30 Coffee break Plenary Session 2 Chairman: Dr.Martin M. Grajower, Assistant Clinical Professor of Medicine, Albert Einstein College of Medicine, Riverdale, NY 15:30-16:00 Genetic studies and immune markers in diabetes – how have they contributed to patient care? Prof. Benjamin Glaser, Head of Endocrinology and Metabolism Service Hadassah, Hebrew University Medical Center, Jerusalem 16:00 Closing remarks Day 2 Wednesday 25 January 2012 Plenary Session 3 Chairman: Prof. Eddy Karnieli, Director, Institute of Endocrinology, Diabetes & Mtabolism, RAMBAM Health Care Campus Prof. Benjamin Glaser, Head of Endocrinology and Metabolism Service, Hadassah, Hebrew University Medical Center, Jerusalem 09:00-09:40 Diabetes, Insulin and Cancer Prof. Derek LeRoith, Director Diabetes and Metabolism, Clinical Research Center of Excellence, Rambam - Health Care Campus, Haifa 09:40-10:20 Diabetes therapy at different stages of the disease Prof. Ralph A. DeFronzo, Professor of Medicine, Chief, Diabetes Division, UTHSCSA and Deputy Director Texas Diabetes Institute 10:20-10:50 Coffee Break Parallel Sessions 3 Complications Obesity Chairmen: Dr. Ilana Harman-Boehm, Head Department of Internal Medicine C Chairmen: Dr. Dan A. Nabriski, Director Institute of Endocrinology, Diabetes & and The Diabetes Unit, Soroka University Medical Center, Beer-Sheva Metabolism, Meir Medical Center, Kfar-Saba Dr. Joelle Singer, Head of Diabetes service, Rabin Medical Center, Beilinson Dr. Faiad Adawi, Vice President of the Israel Diabetes Association. Hospital, Petach Tikva Head of Endocrinology Unit Manager Ziv Medical Center, zefat 10:50-11:10 The Foot Do we really know what nutritional therapy to recommend in Dr. Avivit Cahn, Endocrinology and Metabolism Service, Hadassah, Hebrew diabetes and obesity? University Medical Center, Ein Kerem, Jerusalem Prof. Iris Shai, Researcher of nutrition and chronic diseases, Ben-Gurion University of the Negev 11:10-11:30 The Brain Comparative efficacy and safety of pharmacological approaches Dr. Tali Cukierman-Yaffe, Gertner Institute for Epidemiology, the to the Management of Obesity Endocrinology Institute at Sheba Medical Center and Sackler School of Dr. Dror Dicker, Head of internal medicine D & obesity clinic, Hasharon Medicine at Tel-Aviv University Hospital, Rabin Medical Center, Petach Tikva 11:30-11:50 The Eye Prescribing an exercise regimen for diabetes Dr. Irit Rosenblatt, Head of retinal society - Israel, Department of Dr. Naama Constantini, Dip. Sport Med. (CASM), Director-Sport Medicine Ophthalmology – Rabin medical center, Petah-Tikva Center, Department of Orthopedic Surgery, Hadassah, Hebrew University Medical Center, Jerusalem 11:50-12:10 Steroids and Diabetes Cure of Type 2 Diabetes by metabolic surgery? A critical analysis Prof. Roy E. Weiss, Rabbi Esformes Professor of Medicine and Pediatrics, of the evidence in 2012 state of bariatric surgery in Israel Executive Vice Chairman, Department of Medicine, Chief, Section of Adult and Dr. Andrei Keidar, Head of bariatric surgery clinic, Beilinson Hospital, Rabin Pediatric Endocrinology, Diabetes and Metabolism
Recommended publications
  • Scientific Program

    Scientific Program

    www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ.
  • Dear Colleagues, It Is Our Pleasure to Invite You to the Annual Meeting Of

    Dear Colleagues, It Is Our Pleasure to Invite You to the Annual Meeting Of

    Dear Colleagues, It is our pleasure to invite you to the Annual Meeting of the Israel Neurosurgical Society which will be held at the Galilion Hotel, Israel. Although the main focus of the meeting will be Brain Tumors, the organizers will be happy to consider interesting talks on related subjects. Confirmed speakers to date that will share their experiences and update us in the latest developments include: Prof. Volker A. Coenen Dept. of Stereotactic and Functional Neurosurgery, University of Freiberg; Neurosurgery Clinic, Freiberg, Germany Prof. Garth Rees Cosgrov Dept. of Neurological Surgery, Brigham and Women's Hospital, Boston, MA, USA Prof. Hans Henkes Neuroradiological Clinic, Katharinenhospital, Stuttgart, Germany Prof. Robert H. Rosenwasser Dept. of Neurological Surgery, Jefferson Hospital for Neuroscience, Philadelphia, PA, USA As in previous meetings, we hope that this event will provide the opportunity to reconnect and meet with colleagues and to strengthen professional and personal ties among our members. We hope that you will be able to join us. Sincerely, Prof. Yigal Shoshann Prof. Mony Benifla Dr. Racheli Grossman President Secretary Treasurer 1 TENTATIVE TIMETABLE Wednesday, May 13, 2020 Light Lunch Afternoon Sessions Dinner Evening Social Event Thursday, May 14, 2020 Morning Sessions Lunch Afternoon Sessions Dinner Evening Social Event Friday, May 15, 2020 Morning Sessions Afternoon Sessions End and Light Lunch Meeting Secretariat Target Conferences Ltd. PO Box 51227, Tel Aviv 6713818, Israel Tel: +972 3 5175150, Fax: +972 3 5175155 e-mail: [email protected] www.israelneurosurgery.com 2 SCIENTIFIC ADVISORY COMMITTEE ON FUNCTIONAL NEUROSURGERY AND EPILEPSY Zvi Israel - Lead Advisor Dept. of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem Roberto Spiegelmann Dept.
  • 0201 Haplotype on the Risk for Multiple Sclerosis in Diverse Arab Populations in Israel

    0201 Haplotype on the Risk for Multiple Sclerosis in Diverse Arab Populations in Israel

    Genes and Immunity (2010) 11, 423–431 & 2010 Macmillan Publishers Limited All rights reserved 1466-4879/10 www.nature.com/gene ORIGINAL ARTICLE Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel G Benedek1,6, T Paperna2,6, N Avidan2, I Lejbkowicz2, JR Oksenberg3, J Wang3, C Brautbar1,4, S Israel4 and A Miller2,5, for the Israeli MS Genetics group7 1The Lautenberg Center for Immunology, Hebrew University Hadassah Medical School, Jerusalem, Israel; 2Faculty of Medicine, Rappaport Research Institute, Technion–Israel Institute of Technology, Haifa, Israel; 3Department of Neurology, University of California, San Francisco, CA, USA; 4Tissue Typing and Immunogenetics Unit, Hadassah Medical Center, Jerusalem, Israel and 5Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel Different multiple sclerosis (MS) prevalence rates were reported for Muslim and Christian Arabs in Israel. In this study, we evaluated whether associations of human leukocyte antigen (HLA) genes with MS may contribute to this prevalence difference. DNA samples from Israeli Arab MS patients (n ¼ 109) and controls (n ¼ 132) were typed for HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and -DQB1) genes. Global comparisons of HLA allele frequencies revealed significant differences between Christians and Muslims; therefore, case–control analyses were stratified by religious affiliation. Disease characteristics of Muslim and Christian Arab MS patients were similar to those reported for European populations. Opposing association signals with MS were observed for alleles composing the DRB1*0301-DQB1*0201 haplotype: positive association of the HLA- DRB1*0301 allele in Muslims (PBonferroni ¼ 0.004, odds ratio (OR) ¼ 3.07), and negative association in Christian Arabs (PBonferroni ¼ 0.01, OR ¼ 0.12), with similar results obtained for HLA-DQB1*0201.
  • Spotted Fever Group Rickettsioses in Israel, 2010–2019

    Spotted Fever Group Rickettsioses in Israel, 2010–2019

    Spotted Fever Group Rickettsioses in Israel, 2010–2019 Regev Cohen, Talya Finn, Frida Babushkin, Yael Paran, Ronen Ben Ami, Alaa Atamna, Sharon Reisfeld, Gabriel Weber, Neta Petersiel, Hiba Zayyad, Eyal Leshem, Miriam Weinberger, Yasmin Maor, Nicola Makhoul, Lior Nesher, Galia Zaide, Dar Klein, Adi Beth-Din, Yafi t Atiya-Nasagi ≈ In a multicenter, nationwide, retrospective study of pa- SFGRs are associated with 20 species of Rickettsia, tients hospitalized with spotted fever group rickettsiosis of which 16 are considered human pathogens (1,2). in Israel during 2010–2019, we identifi ed 42 cases, of Recent introduction of molecular methods provided which 36 were autochthonous. The most prevalent spe- more information about SFGR agents causing human cies was the Rickettsia conorii Israeli tick typhus strain (n disease and enabled their identifi cation, for which = 33, 79%); infection with this species necessitated inten- the clinical signifi cance of some remains lacking (3). sive care for 52% of patients and was associated with a R. conorii complex, the etiologic agent of Mediterra- 30% fatality rate. A history of tick bite was rare, found for nean spotted fever, includes 4 strains: R. conorii Mal- only 5% of patients; eschar was found in 12%; and leuko- ish (cause of Mediterranean spotted fever), R. conorii cytosis was more common than leukopenia. Most (72%) Astrakhan (cause of Astrakhan fever), R. conorii In- patients resided along the Mediterranean shoreline. For 3 dian tick typhus (cause of Indian tick typhus), and R. patients, a new Rickettsia variant was identifi ed and had been acquired in eastern, mountainous parts of Israel.
  • Scientific Program

    Scientific Program

    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
  • Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – Does It Matter?

    Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – Does It Matter?

    P13 - Posters - Intensive Cardiac Care Therapeutic Hypothermia for Comatose Patients: VF Versus Other Initial Rhythm – does it Matter? Avishag Laish-Farkash, Shlomi Matetzky, Samer Kassem, Alon Barsheshet, Hanny Haj-Iahia, Nataliya Ulanovsky, Hanoch Hod Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 339 P13 - Posters - Intensive Cardiac Care The Value of Troponin-I Curve after Primary PCI for ST Elevation Myocardial Infarction Avishag Laish-Farkash 1,3, Hanoch Hod 1,3,Ben-Ami Sela2,3,Yoram Amsalem1,3, Athanasios Michailidis 1, Shlomi Matetzky 1,3 1 Heart Institute, 2 Institute for Chemical Pathology, Sheba Medical Center, Tel Hashomer, 3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 340 P13 - Posters - Intensive Cardiac Care C-Reactive Protein as a Predictor of Active Coronary Disease and Worse Prognosis in Chest Pain Unit Dan Oieru 1,Roy Beigel1, Hanoch Hod 1,2, Pierre Chouraqui 1,2,Orly Goitein1, Eli Konen 1, Roy Beinart 1,Paul Fefer1,Ben-Ami Sela3,Ari Shamiss4,Jacob Or5, Shlomi Matetzky 1,2 1 Heart Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 3 Biochemical Laboratory, 4 Hospital Director, 5 Emergency Department, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel The 55th Annual Conference of the I.H.S and the I.S.C.S 341 P13 - Posters - Intensive
  • Curriculum Vitae Shay Schneider, M.D

    Curriculum Vitae Shay Schneider, M.D

    April, 2020 Curriculum Vitae Shay Schneider, M.D Name: Shay Schneider Date of birth: December 23, 1979 Place of birth: Tel Aviv, Israel Family status: Married +2 Telephone: +972-54-7685189 E mail: [email protected] CLINICAL EXPERIENCE Sep 2018-present: Senior staff member Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Sep 2018-Sep 2020: Clinical Fellow (Rhinology and skull base surgery), A.R.M, Center of Otolaryngology/ Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel. Sep 2012-Sep 2018: Resident: Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Jan 2011 - Jan 2012: Rotating internship year: Training physician in internal medicine, general surgery, anesthesia and pediatrics units, Barzilai Medical Center in Ashkelon, Israel. Jun 2009 - Aug 2009: Clinical rotation in Otolaryngology, Shaare Zedek Medical Center in Jerusalem, Israel. ACADEMIC DEGREES 2016- present: Instructor, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel. 2004-2010: MD degree, Third Medical Faculty, Charles University in Prague (English program), Czech Republic. POST ACADEMIC COURSES Jan 2020: Baloon sinuplasty and Eustachian tuboplasty, Madeira, Portugal. Aug-Sep 2018: Observership, University of Texas MD Anderson Cancer Center, Houston, Texas. United States 2013-2018: School of Continuing Studies, Otolaryngology program, The Sackler Faculty of Medicine, Tel Aviv University, Israel. June 2017: Rhinoplasty course, Ziv Medical Center, Israel Feb 2017: 4th Annual OSAS International Surgery Course, Florida Hospital Nicholson Center & Florida Hospital Celebration Health, Celebration, United States. Feb 2017: Trans- oral laser surgery (TLS) course, Kaplan Medical Center. Sep 2016: Head and neck dissection course, Tel Aviv University. Oct 2014: Sedation course, Sheba Medical Center, Tel Aviv.
  • Antibiotic Treatment for Invasive Listeriosis and Patient

    Antibiotic Treatment for Invasive Listeriosis and Patient

    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
  • Mortality of Patients with Rheumatoid Arthritis Requiring Intensive Care: a Single-Center Retrospective Study

    Mortality of Patients with Rheumatoid Arthritis Requiring Intensive Care: a Single-Center Retrospective Study

    Clinical Rheumatology (2019) 38:3015–3023 https://doi.org/10.1007/s10067-019-04651-w ORIGINAL ARTICLE Mortality of patients with rheumatoid arthritis requiring intensive care: a single-center retrospective study Yael Haviv-Yadid1 & Yulia Segal2 & Amir Dagan3,4,5 & Kassem Sharif6 & Nicola Luigi Bragazzi7 & Abdulla Watad6 & Howard Amital6,8,9 & Yehuda Shoenfeld8,9,10,11 & Ora Shovman6,8,9 Received: 20 February 2019 /Revised: 10 June 2019 /Accepted: 18 June 2019 /Published online: 26 June 2019 # International League of Associations for Rheumatology (ILAR) 2019 Abstract Background Patients with rheumatoid arthritis (RA) are at a high risk for life-threatening conditions requiring admission to the intensive care unit (ICU), but the data regarding the outcomes of these patients is limited. The present study investigated the clinical characteristics and outcomes of RA patients admitted to an ICU. Methods This retrospective cohort study included RA patients admitted to the general ICU of the Sheba Medical Center during 2002–2018. The main outcome was 30-day mortality. Using Student’s t test, χ2, and multivariable analyses, we compared the demographic, clinical, and laboratory parameters of the survivors and the non-survivors. Figures with p value < 0.05 were considered statistically significant. Results Forty-three RA patients were admitted to the ICU during the study period (mean age, 64.0 ± 13.1 years; 74.4% female). The leading causes of ICU admission were infection (72.1%), respiratory failure (72.1%), renal failure (60.5%), and septic shock (55.8%). The 30-day mortality rate was 34.9%, with infection (9/15, 60%) as the most frequent cause.
  • December 2013 Prof. Reuven Zimlichman Chief of Medicine and Hypertension Institute, the E

    December 2013 Prof. Reuven Zimlichman Chief of Medicine and Hypertension Institute, the E

    R. Zimlichman M.D. December 2013 Prof. Reuven Zimlichman Chief of Medicine and Hypertension Institute, The E. Wolfson Medical Center P.O.B. 5, Holon 58100 Israel and Head of Cardiovascular Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel Phone: 972-3-5028614, FAX: 972-3- 5032693 e-mail: [email protected] Prof. R. Zimlichman, M.D. is presently Chief Departments of Medicine and Head of Hypertension Institute at the E. Wolfson Medical Center, Israel, he is the Director of The Brunner Cardiovascular Research Institute, Tel-Aviv University. He is also the immediate past Vice Dean and Head of School of Continuing Education, Sackler Faculty of Medicine, Tel Aviv University. Prof. Zimlichman did his fellowship in Hypertension at the Hypertension Endocrine Branch, NIH, NHLBI in Bethesda, Maryland, USA (1983 to 1986). During the following years he returned for prolonged periods of research in the Hypertension Endocrine Branch and in the Clinical Neurocardiology section. Prof. Zimlichman joined the Faculty of Health Sciences at Ben Gurion University and Soroka Medical Center in Beer Sheva, Israel. He was nominated as Chief of Clinical and Experimental Hypertension in the Faculty of Medicine and in the Medical Center. Prof. Zimlichman was nominated as Chief of Medicine in the Sheba Medical Center, Tel Hashomer, in 1989 and was nominated as Associate Professor in Medicine at the Tel Aviv University, Sackler School of Medicine in 1994. In 1991 Prof Zimlichman was nominated as Chief of Department of Medicine in the Wolfson Medical Center, and in 1998 was nominated as Chief Departments of Medicine at the Wolfson Medical Center.
  • APF Newsletter, Winter 2006 – 2007

    APF Newsletter, Winter 2006 – 2007

    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted